Usefulness of the CAT, LCOPD, EQ-5D and COPDSS Scales in Understanding the Impact of Lung Disease in Patients with Alpha-1 Antitrypsin Deficiency

References

• Luisetti M, Seersholm N. α1-Antitrypsin deficiency·1: Epidemiology of α1-antitrypsin deficiency. Thorax 2004; 59: 164–169.
   PubMed Web of Science ®Google Scholar
• Miravitlles M. Alpha-1-antitrypsin and other proteinase inhibitors. Curr Opin Pharmacol 2012; 12: 309–314.
   PubMed Web of Science ®Google Scholar
• Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe a1-antitrypsin deficiency (PiZZ). Eur Respir J 1999; 13: 247–251.
   PubMed Web of Science ®Google Scholar
• Tirado-Conde G, Lara B, Casas F, Blanco I, Bustamante A, Cadenas S, Factors associated with the evolution of lung function in patients with alpha-1 antitrypsin deficiency in the Spanish Registry. Arch Bronconeumol 2011; 47: 495–503.
   PubMed Web of Science ®Google Scholar
• Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res 2011; 12: 161.
   PubMed Web of Science ®Google Scholar
• Renwick DS, Connolly MJ. Impact of obstructive airways disease on quality of life in older adults. Thorax 1996; 51: 520–525.
   PubMed Web of Science ®Google Scholar
• Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar C, Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127: 1072–1079.
   PubMed Web of Science ®Google Scholar
• Campos MA, Alazemi S, Zhang G, Salathe M, Wanner A, Sandhaus RA, Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years. Chest. 2009; 135: 600–608.
   PubMed Web of Science ®Google Scholar
• Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha-1 antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001; 164: 1805–1809.
   PubMed Web of Science ®Google Scholar
• Dowson LJ, Guest PJ, Stockley RA. The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in alpha-1 antitrypsin deficiency (PiZ). Chest 2002; 122: 1247–1255.
   PubMed Web of Science ®Google Scholar
• Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581–586.
   PubMed Web of Science ®Google Scholar
• Eisner MD, Trupin L, Katz PP, Yelin EH, Earnest G, Balmes J, Development and validation of a survey-based COPD Severity Score. Chest 2005; 127: 1890–1897.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Llor C, de Castellar R, Izquierdo I, Baró E, Donado E. Validation of the COPD severity score for its use in Primary Care. The NEREA study. Eur Respir J 2009; 33: 519–527.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.
   PubMedGoogle Scholar
• EuroQoL Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208.
   PubMed Web of Science ®Google Scholar
• Badia X, Roset M, Montserrat S, Herdman M, Segura A. The Spanish version of EuroQol: a description and its applications. European quality of life scale. Med Clin (Barc) 1999; 112(Suppl 1):e79–e85.
   PubMed Web of Science ®Google Scholar
• McKenna SP, Meads DM, Doward LC, Twiss J, Pokrzywinski R, Revicki D, Hunter CJ, Glendenning GA. Development and validation of the living with chronic obstructive pulmonary disease questionnaire. Qual Life Res 2011; 20: 1043–1052.
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Leidy KN. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648–654.
   PubMed Web of Science ®Google Scholar
• Silverman EK, Pierce JA, Province MA, Rao DC, Campbell EJ. Variability of pulmonary function in alpha-1 antitrypsin deficiency: clinical correlates. Ann Intern Med 1989; 111: 982–991.
   PubMed Web of Science ®Google Scholar
• Piras B, Ferrarotti I, Lara B, Martinez MT, Bustamante A, Ottaviani S, Characteristics of Italian and Spanish patients with alpha-1-antitrypsin deficiency: Identifying clinical phenotypes. Eur Respir J 2013; 42: 54–64.
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85(Suppl B): 25–31.
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.
   PubMed Web of Science ®Google Scholar
• Campos MA, Alazemi S, Zhang G, Wanner A, Salathe M, Baier H, Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Respir Med 2009; 103: 1532–1539.
   PubMed Web of Science ®Google Scholar
• Needham M, Stockley RA. Exacerbations in alpha-1 antitrypsin deficiency. Eur Respir J 2005; 25: 992–1000.
   PubMed Web of Science ®Google Scholar
• Stolk J, Ng WH, Bakker ME, Reiber JHC, Rabe KF, Putter H, Stoel BC. Correlation between anual change in health status and computer tomography derived lung density in subjects with alpha-1 antitrypsin deficiency. Thorax 2003; 58: 1027–1030.
   PubMed Web of Science ®Google Scholar
• Dowson LJ, Newall C, Guest PJ, Hill SL, Stockley RA. Exercise capacity predicts health status in alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2001; 163: 936–941.
   PubMed Web of Science ®Google Scholar
• Holm KE, Borson S, Sandhaus RA, Ford DW, Strange C, Bowler RP, Differences in adjustement between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD. COPD 2013; 10: 226–234.
   PubMedGoogle Scholar
• Jones P, Miravitlles M, van der Molen T, Kulich K. Beyond FEV1 in COPD—A review of patient-reported outcomes and their measurement using a new generation of instruments. Int J Chron Obst Pulm Dis 2012; 7: 697–709.
   PubMed Web of Science ®Google Scholar
• Edgar RG, Griffiths D, Stockley RA. Validations of the COPD Assessment Test (CAT) whithin alpha-1 antitrypsin deficiency (AATD). Thorax 2010; 65: A141.
   Web of Science ®Google Scholar
• Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J 2011; 38: 29–35.
   PubMed Web of Science ®Google Scholar
• Pillai AP, Turner AM, Stockley RA. Global initiative for chronic obstructive lung disease 2011 symptom/risk assessment in α1-antitrypsin deficiency. Chest 2013; 144: 1152–1162.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD. Arch Bronconeumol 2012; 48: 247–257.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Iriberri M, Barrueco M, Lleonart M, Villarrubia E, Galera J. Usefulness of the LCOPD, CAFS, and CASIS scales in understanding the impact of COPD on patients. Respiration 2013; 86: 190–200.
   PubMed Web of Science ®Google Scholar
• McKenna SP, Twiss J, Crawford SR, Oprandi NC, Tammaru M, Miravitlles M. Adapting the Living with Chronic Obstructive Pulmonary Disease (LCOPD) for use in Southern European (Italian and Spanish) and Eastern European (Russian) cultures. J Clin Epidemiol 2012; 65: 906–914.
   PubMed Web of Science ®Google Scholar
• Eisner MD, Omachi TA, Katz PP, Yelin EH, Iribarren C, Blanc PD. Measurement of COPD severity using a survey-based score: validation in a clinically and physiologically characterized cohort. Chest 2010; 137: 846–851.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Izquierdo I, Herrejon A, Torres VJ, Baró E, Borja J. On behalf of the ESFERA investigators COPD severity score as a predictor of failure in exacerbations of COPD. The ESFERA study. Respir Med 2011; 105: 740–747.
   PubMed Web of Science ®Google Scholar